98%
921
2 minutes
20
Using computational methods to personalize drug response prediction holds great promise to improve cancer therapy. Most existing methods use either biochemical information or response-related networks to predict drug response, nevertheless, the information they considered is not comprehensive. In this study, we present a novel end-to-end deep learning-based method Graph Neural Network with multi-task learning for Drug Response Prediction (GNNDRP). It leverages biochemical features as well as the hidden features from the heterogeneous network which incorporates the known drug-cell line responses, drug similarities, and cell line similarities, to complete the drug response prediction task. Moreover, GNNDRP designs a self-supervised task to enhance the representation capacity from the response network and further improve the model prediction performance. Extensive experiments show that GNNDRP outperforms existing state-of-the-art prediction methods under various experimental settings. The ablation analysis reveals that the biochemical characteristics, response-related network, and our self-supervised strategy can boost the predictive power. Additionally, case studies further validate the effectiveness of GNNDRP in identifying novel drug-cell line responses.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/TCBBIO.2025.3548692 | DOI Listing |
Int J Pharm X
June 2025
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China.
Ultra-sensitive pH-responsive drug delivery system designed to operate within the slightly acidic microenvironment of tumors are highly desired for hydrogel applications in cancer therapy. In this study, 4-Formylbenzoic acid modified polyvinyl alcohol (PVA-FBA, PF) was synthesized and utilized as a carrier for encapsulating the anticancer drug Doxorubicin (Dox). This was subsequently crosslinked with polyethylenimine (PEI) via benzoic-imine bond to form drug-loaded PVA-FBA/PEI hydrogel (D-PFP).
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
Cancer is a multifaceted disease driven by a complex interplay of genetic predisposition, environmental factors and lifestyle habits. With the accelerating pace of cancer research, the gut microbiome has emerged as a critical modulator of human health and immunity. Disruption in the gut microbial populations and diversity, known as dysbiosis, has been linked with the development of chronic inflammation, oncogenesis, angiogenesis and metastasis.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Hematology, Cancer Center, the First Hospital of Jilin University, Changchun, China.
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome that is caused primarily by immune-mediated destruction of hematopoietic stem cells. Traditional treatment relies on immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CSA). However, the toxicity and limited availability of ATG have spurred interest in ATG-free regimens.
View Article and Find Full Text PDFFront Immunol
September 2025
Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Background: Cryopyrin-associated periodic syndrome (CAPS) is an autoinflammatory disease caused by a gain-of-function mutation in the gene, which regulates inflammasome-mediated interleukin-1β (IL-1β) production. This leads to recurrent episodes of fever, rash, and arthritis, typically beginning in childhood.
Objective: To demonstrate the role of a missense mutation, c.
Front Immunol
September 2025
Precision Pharmacy and Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Gliomas are the most common primary malignant tumors of the central nervous system (CNS), and despite progress in molecular diagnostics and targeted therapies, their prognosis remains poor. In recent years, immunotherapy has emerged as a promising treatment modality in cancer therapy. However, the inevitable immune evasion by tumor cells is a key barrier affecting therapeutic efficacy.
View Article and Find Full Text PDF